BNY Mellon DRs Proudly Announces the Launch of


Our objective is to assist issuer clients in developing an effective ESG strategy, fully integrated into their capital markets and investor relations activities. As market developments provide new risks and opportunities for issuers, we want to ensure our clients are at the forefront of understanding how best to respond to these developments. For more information, read our latest brochure and click on the video featuring Guy Gresham, Global IR Advisory Head at BNY Mellon Depositary Receipts.

Click to read the brochure>>


September 2015

An active area of recent U.S. investor interest has been the Pharmaceuticals & Biotechnology / Health Care Equipment & Services sectors. As of June 30, 2015, Pharma & Biotech / Health Care companies were the most active issuers of new ADR programs to day. BNY Mellon Depositary Receipts is focused on the unique needs of ADR issuers in these sectors.

For more information, read our latest brochure: The Benefits of Utilizing Depositary Receipts - Pharmaceuticals & Biotechnology / Health Care Equipment & Services Sectors.

Click to read the brochure>>


Discover how BNY Mellon helped broaden a surgical robotics company's investor base and capital markets reach.

"......In financial services, it is often difficult to see the results of your work. However, in this case, with Mazor, it was very easy."

Anthony Moro
Head of EMEA, Depositary Receipts

BNY Mellon was able to help Mazor Robotics raise capital through a Depositary Receipt program to realize its business goals for its revolutionary spinal surgery technology.

Click to see the story here.>>

Powered by Interactive Data Managed Solutions

© 2015 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.